An international group of 56 health organizations and medical experts has renamed the condition formerly known as Polycystic Ovary Syndrome (SOP) [1].

The change aims to shift the medical focus away from the presence of ovarian cysts and toward the systemic hormonal and metabolic disruptions that characterize the disorder. By updating the terminology, health professionals intend to improve diagnostic accuracy and patient care for a condition that affects a significant portion of the population.

According to an announcement published in The Lancet and reported by Brazilian media on May 12, 2026 [1], the condition is now called Metabolic Polyendocrine Ovarian Syndrome (SOMP) [2]. The transition to SOMP acknowledges that the disorder is not merely a reproductive issue but a complex metabolic syndrome [3].

Experts involved in the consensus said the previous name was misleading because it emphasized cysts that are not always present or the primary driver of the patient's symptoms [4]. The new name highlights the "polyendocrine" nature of the condition, meaning it involves multiple endocrine glands, and its "metabolic" impact, such as insulin resistance [2].

This global agreement involved 56 organizations [1]. The move is intended to standardize how the condition is identified across different healthcare systems and ensure that clinicians look beyond the ovaries when treating patients [5].

Medical practitioners said the updated nomenclature will help patients understand that their symptoms, ranging from irregular periods to weight gain and skin changes, are linked to a broader metabolic dysfunction [6]. The change is expected to influence clinical guidelines and the way the condition is taught in medical schools globally [2].

“The condition is now called Metabolic Polyendocrine Ovarian Syndrome (SOMP).”

The renaming of SOP to SOMP represents a paradigm shift in endocrinology. By removing the focus from 'cysts'—which can be found in women without the syndrome—and emphasizing 'metabolic' and 'polyendocrine' factors, the medical community is prioritizing the underlying cause of the disease over a secondary symptom. This likely leads to more comprehensive screening for metabolic disorders like type 2 diabetes and cardiovascular issues in affected patients.